Smart Decision, Inc., is Now Patent Pending for Automated CBD Product Recommendation System and Method
Boca Raton, FL, Aug. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Smart Decision, Inc. (OTC Pink Markets: SDEC), a next-generation consumer-based LED & CBD algorithm innovator, is pleased to announce that it has become patent pending with a method to help consumers select the right CBD products for their needs. Smart Decision, Inc. believes that both CBD manufacturers and consumers will benefit from the latest addition to its patent portfolio.
"While the CBD industry has enjoyed a meteoric rise during the past couple of years, the confusion that still exists in the marketplace has kept far too many consumers on the sidelines. With our latest Intellectual Property (IP) filing, we anticipate an increased acceptance and understanding of CBD at the consumer level that will increase CBD usage in the U.S," said Adam Green, CEO of Smart Decision, Inc.
Eric Gutmann, Treasurer & Secretary of Smart Decision, Inc. further states, “For the past few years, CBD manufacturers have tried to increase consumer demand with educational research. We believe that our filing is a welcomed step in easing consumer apprehension that currently exists in the CBD space.”
Smart Decision, Inc. expects to provide more details and algorithm demos in the near future.
About Smart Decision Inc.
Smart Decision Inc. has researched and is developing algorithms for the consumer and business LED Lighting and CBD markets. With their patent-pending “Smart Decision” algorithms, the confusion of selecting the right product(s), whether for LED or CBD, will be significantly reduced. Ultimately, Smart Decision Inc. believes that selecting the right product the first time, dramatically cuts down on product returns and creates of positive purchasing experience for the consumer.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for 10,000 U.S. and global securities. Through OTC Link ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to access to capital, liquidity, increased visibility, our growth strategy and product development, updates on the CRADA, and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our dependence on third-party suppliers and partners; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. Important factors that may cause the actual results to differ from those expressed within may include, but are not limited to: the success or failure of Smart Decision’s efforts to successfully market its camera; systems, other products and services as scheduled; Smart Decision’s ability to attract and retain quality employees; the effect of changing economic conditions; increased competition; the ability of Smart Decision to obtain adequate debt or equity financing. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
For more information, please contact:
Adam Green, CEO
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)